進行性運動失調症および筋力低下症治療薬の世界市場

世界の進行性運動失調症および筋力低下症治療薬の市場規模は、2022年の320億米ドル、2023年の351億米ドルから、予測期間中は10.2%のCAGRで推移し、2028年には572億米ドルの規模に成長すると予測されています。

進行性筋力低下症の部門は、2022年の299億米ドル、2023年の328億米ドルから、10.0%のCAGRで推移し、2028年には528億米ドルに達すると予測されています。また、進行性運動失調症の部門は、2022年の21億米ドル、2023年の24億米ドルから、13.3%のCAGRで推移し、2028年には44億米ドルの規模に成長すると予測されています。

当レポートでは、世界の進行性運動失調症および筋力低下症治療薬の市場を調査し、疾患の概要・分類、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、技術および特許の動向、ESGの展開、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場概要

• 定義
• 分類
• 進行性運動失調症および筋力低下症
• 進行性運動失調症および筋力低下症の診断検査

第4章 市場力学

• 市場促進要因
• 市場の障壁
• 市場機会
• COVID-19の市場への影響

第5章 市場内訳：タイプ・技術別

• タイプ別
• 市場概要
• 市場収益
• 技術別
• 市場概要
• 市場収益
• 低分子
• 市場概要
• 市場収益
• モノクローナル抗体
• 市場概要
• 市場収益
• その他
• バイオマーカー
• 遺伝子治療
• 幹細胞
• 市場概要
• 市場収益

第6章 市場内訳：疾患別

• 概要
• 市場収益
• 進行性運動失調症のタイプ別市場
• フリードライヒ失調症
• 市場収益
• マシャドジョセフ病 (MJD) /SCA3
• 市場収益
• ゲルストマンストロイスラーシャインカー病
• 市場収益
• 疾患タイプ別市場
• 筋萎縮性側索硬化症
• 進行性球麻痺
• 遺伝性痙性対麻痺
• 遺伝性神経障害 (HN)
• 多発性硬化症 (MS)

第7章 市場内訳：地域別

• 北米
• 米国
• カナダ
• 欧州
• 英国
• ドイツ
• フランス
• スペイン
• イタリア
• ロシア
• その他の欧州
• アジア太平洋
• 日本
• 中国
• インド
• オーストラリア
• その他のアジア太平洋地域
• 世界のその他の地域
• 市場規模・予測

第8章 市場内訳：流通チャネル別

• 小売薬局
• 病院薬局
• オンライン薬局

第9章 新たな技術と開発

• 新興技術
• 幹細胞療法
• 遺伝子療法
• バイオマーカー
• MS用点鼻薬
• 疾患修飾療法
• RNAベース療法
• 総論

第10章 ESGの展開

• 主要企業によるESG投資
• ESGに対する消費者の意識
• 総論

第11章 特許分析

第12章 M&Aおよびベンチャー資金調達の見通し・競合情勢

• M&A・提携
• 戦略的取り組み
• 製造業者の市場シェア

第13章 企業プロファイル

• ABBOTT LABORATORIES
• ACORDA THERAPEUTICS INC.
• AMERICAN REGENT INC.
• APOTEX INC.
• APOTHECA INC.
• ASTELLAS PHARMA INC.
• ASTRAZENECA GMBH
• BAXTER INTERNATIONAL INC.
• BRISTOL-MYERS SQUIBB
• EISAI CO. LTD.
• ELI LILLY AND COMPANY
• GILEAD SCIENCES INC.
• GLAXOSMITHKLINE PLC
• GLENMARK LIFE SCIENCES
• JOHNSON & JOHNSON
• MERCK KGAA
• NOVARTIS AG
• PFIZER INC.
• ROCHE HOLDING LTD.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.

第14章 付録：略語

List of Tables

• Summary Table A : Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorder Drugs, Through 2028
• Summary Table B : Global Market for Progressive Ataxia and Weakness Disorders, Through 2028
• Table 1 : Classification, by Primary Dysfunction
• Table 2 : Drugs Approved in Europe for Multiple Sclerosis, 2011-2022
• Table 3 : Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, Through 2028
• Table 4 : Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, Through 2028
• Table 5 : Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
• Table 6 : Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
• Table 7 : Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
• Table 8 : Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, Through 2028
• Table 9 : Global Market for Friedreich's Ataxia Drugs, by Region, Through 2028
• Table 10 : Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, Through 2028
• Table 11 : Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, Through 2028
• Table 12 : Latest FDA Approvals for Amyotrophic Lateral Sclerosis
• Table 13 : Drugs in Clinical Trials for ALS, 2022
• Table 14 : Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, Through 2028
• Table 15 : Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, Through 2028
• Table 16 : Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, Through 2028
• Table 17 : Global Market for Hereditary Neuropathies Drugs, by Region, Through 2028
• Table 18 : Latest FDA Approvals for Multiple Sclerosis
• Table 19 : Global Market for Multiple Sclerosis (MS) Drugs, by Region, Through 2028
• Table 20 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, Through 2028
• Table 21 : North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
• Table 22 : European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
• Table 23 : Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
• Table 24 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, Through 2028
• Table 25 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, Through 2028
• Table 26 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, Through 2028
• Table 27 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, Through 2028
• Table 28 : ESG Ranking of Major Players,2022
• Table 29 : ESG Investments, by Key Players, 2022
• Table 30 : ESG Trends, Major Players, 2021
• Table 31 : ESG Rankings for Major Companies, 2023
• Table 32 : CDP Scope Card for Major Players, 2022
• Table 33 : Patent Analysis, by Year, Jan. 2020 to March 2023
• Table 34 : Major Companies Patents: 2022 to March 2023
• Table 35 : M&A: Pharmaceutical Companies
• Table 36 : Abbott Laboratories: Annual Revenue, 2022
• Table 37 : Abbott Laboratories: News
• Table 38 : Abbott Laboratories.: Product Portfolio
• Table 39 : Acorda Therapeutics Inc.: News
• Table 40 : Acorda Therapeutics Inc.: Product Portfolio
• Table 41 : Eli Lily and Company: Annual Revenue, 2022
• Table 42 : Eli Lily and Company: News
• Table 43 : Eli Lily and Company: Product Portfolio
• Table 44 : GlaxoSmithKline PLC: Annual Revenue, 2022
• Table 45 : GlaxoSmithKline PLC: News
• Table 46 : GlaxoSmithKline PLC: Product Portfolio
• Table 47 : Glenmark Life Sciences: Annual Revenue, 2022
• Table 48 : Glenmark Life Sciences: Product Portfolio
• Table 49 : Novartis AG: Annual Revenue, 2022
• Table 50 : Novartis AG: News
• Table 51 : Novartis AG: Product Portfolio
• Table 52 : Pfizer Inc.: Annual Revenue, 2022
• Table 53 : Pfizer Inc.: News
• Table 54 : Pfizer Inc.: Product Portfolio
• Table 55 : Roche Holding Ltd.: Annual Revenue, 2022
• Table 56 : Roche Holding Ltd.: News
• Table 57 : Roche Holding Ltd.: Product Portfolio
• Table 58 : Sanofi: Annual Revenue, 2022
• Table 59 : Sanofi: News
• Table 60 : Sanofi: Product Portfolio
• Table 61 : Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2022
• Table 62 : Takeda Pharmaceutical Co. Ltd.: News
• Table 63 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
• Table 64 : Teva Pharmaceutical Industries LTD.: Annual Revenue, 2022
• Table 65 : Teva Pharmaceutical Industries LTD.: Product Portfolio
• Table 66 : Abbreviations

List of Figures

• Summary Figure A : Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Summary Figure B : Global Market for Progressive Ataxia and Weakness Disorders, 2020-2028
• Figure 1 : Share of Global Health Expenditure Database, 2022
• Figure 2 : Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2020-2028
• Figure 3 : Global Market Shares of Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2022
• Figure 4 : Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2020-2028
• Figure 5 : Global Market Shares of Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2022
• Figure 6 : Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
• Figure 7 : Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
• Figure 8 : Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
• Figure 9 : Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2020-2028
• Figure 10 : Global Market Shares of Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2022
• Figure 11 : Global Market for Friedreich's Ataxia Drugs, by Region, 2020-2028
• Figure 12 : Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, 2020-2028
• Figure 13 : Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, 2020-2028
• Figure 14 : Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, 2020-2028
• Figure 15 : Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, 2020-2028
• Figure 16 : Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, 2020-2028
• Figure 17 : Global Market for Hereditary Neuropathies Drugs, by Region, 2020-2028
• Figure 18 : Global Market for Multiple Sclerosis (MS) Drugs, by Region, 2020-2028
• Figure 19 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, 2020-2028
• Figure 20 : Global Market Shares of Progressive Ataxia and Weakness Disorders Drugs, by Region, 2022
• Figure 21 : North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
• Figure 22 : U.S. Market for Progressive Ataxia and Weakness Disorders Drug, 2020-2028
• Figure 23 : Canadian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 24 : European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
• Figure 25 : UK Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 26 : German Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 27 : French Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 28 : Spanish Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 29 : Italian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 30 : Russian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 31 : Rest of European Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 32 : Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
• Figure 33 : Japanese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 34 : Chinese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 35 : Indian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 36 : Australian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 37 : Rest of Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 38 : Rest of the World Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
• Figure 39 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, 2020-2028
• Figure 40 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, 2020-2028
• Figure 41 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, 2020-2028
• Figure 42 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, 2020-2028
• Figure 43 : Benefits of Stem Cell Therapy for the Treatment of Syndrome of Progressive Ataxia and Weakness Disorders
• Figure 44 : Environmental, Social and Governance Factors in the Pharmaceutical Industry for Syndromes of Progressive Ataxia and Weakness Disorders Market
• Figure 45 : How A Strong ESG Proposition Benefits Pharmaceutical Business
• Figure 46 : Share of ESG-Geographical Adoption Level Across All Industries, 2022
• Figure 47 : Shares of Patents Registered/Approved, by Country, Jan. 2020 to July 2023
• Figure 48 : Global Progressive Ataxia and Weakness Disorders Drugs Market Shares, by Key Manufacturers, 2022
• Figure 49 : Abbott Laboratories: Annual Revenue, 2021 and 2022
• Figure 50 : Abbott Laboratories: Revenue Shares, by Business Unit, 2022
• Figure 51 : Abbott Laboratories.: Revenue Shares, by Region/Country, 2022
• Figure 52 : Eli Lily and Company: Annual Revenue, 2021 and 2022
• Figure 53 : Eli Lily and Company: Revenue Shares, by Business Unit, 2022
• Figure 54 : Eli Lily and Company: Revenue Shares, by Region/Country, 2022
• Figure 55 : GlaxoSmithKline PLC: Annual Revenue, 2021 and 2022
• Figure 56 : GlaxoSmithKline PLC: Revenue Shares, by Business Unit, 2022
• Figure 57 : GlaxoSmithKline PLC: Revenue Shares, by Region/Country, 2022
• Figure 58 : Glenmark Life Sciences: Annual Revenue, 2021 and 2022
• Figure 59 : Glenmark Life Sciences: Revenue Shares, by Business Unit, 2022
• Figure 60 : Novartis AG: Annual Revenue, 2021 and 2022
• Figure 61 : Novartis AG: Revenue Shares, by Business Unit, 2022
• Figure 62 : Novartis AG: Revenue Shares, by Region, 2022
• Figure 63 : Pfizer Inc.: Annual Revenue, 2021 and 2022
• Figure 64 : Pfizer Inc.: Revenue Shares, by Business Unit, 2022
• Figure 65 : Pfizer Inc.: Revenue Shares, by Region/Country, 2022
• Figure 66 : Roche Holding Ltd.: Annual Revenue, 2021 and 2022
• Figure 67 : Roche Holding Ltd.: Revenue Shares, by Business Unit, 2022
• Figure 68 : Roche Holding Ltd.: Revenue Shares, by Region, 2022
• Figure 69 : Sanofi: Annual Revenue, 2021 and 2022
• Figure 70 : Sanofi: Revenue Shares, by Business Unit, 2022
• Figure 71 : Sanofi: Revenue Shares, by Region/Country, 2022
• Figure 72 : Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2021 and 2022
• Figure 73 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, 2022
• Figure 74 : Takeda Pharmaceutical Company Limited: Revenue Shares, by Region/Country, 2022
• Figure 75 : Teva Pharmaceutical Industries LTD.: Annual Revenue, 2021 and 2022
• Figure 76 : Teva Pharmaceutical Industries LTD.: Revenue Shares, by Business Unit, 2022
• Figure 77 : Teva Pharmaceutical Industries LTD.: Revenue Shares, by Region, 2022

Highlights:

The global progressive ataxia and weakness disorders market reached $32.0 billion in 2022, should reach $35.1 billion by 2023 and $57.2 billion by 2028 with a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2023-2028.

Progressive weakness syndromes segment of the global progressive ataxia and weakness disorders market reached $29.9 billion in 2022, should reach $32.8 billion by 2023 and $52.8 billion by 2028 with a CAGR of 10.0% during the forecast period of 2023-2028.

Progressive ataxia segment of the global progressive ataxia and weakness disorders market reached $2.1 billion in 2022, should reach $2.4 billion by 2023 and $4.4 billion by 2028 with a CAGR of 13.3% during the forecast period of 2023-2028.

Report Scope:

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.

This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.

Report Includes:

• 34 data tables and 34 additional tables
• A comprehensive overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
• Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
• In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall market
• Estimation of the actual market size and revenue forecast for global progressive ataxia and weakness disorders treatments market in USD million values, and corresponding market share analysis based on product, technology, disease type, application, distribution channel, and region
• Discussion of the applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology
• Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market growth
• Review of key patent grants and recent patent applications on neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets, along with emerging technologies and new developments
• Coverage of recent merger and acquisition (M&A) activities, venture fundings, and other impactful growth strategies in the global market neurodegenerative (i.e., progressive ataxia and weakness) disorders
• Identification of the key players operating in the market, and analysis of their competitive landscape based on recent developments, segmental revenues, and operational integration
• Company profiles of major players within the industry, including Abbott Laboratories, Glenmark Life Sciences, Novartis AG, Pfizer Inc., Roche Holding Ltd., and Sanofi

Table of Contents

Chapter 1 Introduction

• Overview
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in This Update?
• Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Overview

Chapter 3 Market Overview

• Introduction
• Definitions
• Neurons
• Central Nervous System
• Brain
• Spinal Cord
• Neurotransmitters
• Classification
• Progressive Ataxia and Weakness Disorders
• Friedreich's Ataxia
• Gertsmann-Straussler-Scheinker Disease
• Machado-Joseph Disease/SCA3
• Amyotrophic Lateral Sclerosis
• Hereditary Spastic Paraplegia
• Hereditary Neuropathies
• Multiple Sclerosis
• Diagnostic Tests for Progressive Ataxia and Weakness Disorders
• Diagnostic Tests for Multiple Sclerosis
• Diagnostic Tests for Amyotrophic Lateral Sclerosis
• Diagnostic Tests for Friedreich's Ataxia
• Diagnostic Tests for Machado-Joseph Disease
• Diagnostic Tests for Hereditary Spastic Paraplegia
• Diagnostic Tests for Hereditary Neuropathies

Chapter 4 Market Dynamics

• Introduction
• Market Drivers
• Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
• Technological Advancements and Product Launch
• Increasing Expenditures for Health Care
• Rise in Alcohol and Drug Use
• Market Barriers
• Barriers to R&D for Progressive Ataxia
• Diagnostic Challenges
• Opportunities
• Advancements in Research and Technology
• Impact of COVID-19, Global Market for Treatment for Syndromes of Progressive Ataxia and Weakness Disorders

Chapter 5 Market Breakdown by Type and Technology

• Introduction
• Market by Type
• Market Overview
• Market Revenue
• Market by Technology
• Market Overview
• Market Revenue
• Small Molecule
• Market Overview
• Market Revenue
• Monoclonal Antibody
• Market Overview
• Market Revenue
• Others
• Biomarkers
• Gene Therapy
• Stem Cell
• Market Overview
• Market Revenue

Chapter 6 Market Breakdown by Disease

• Overview
• Market Revenue
• Market by Progressive Ataxia Diseases Type
• Friedreich's Ataxia
• Market Revenue
• Machado-Joseph disease (MJD)/SCA3
• Market Revenue
• Gertsmann-Straussler-Scheinker Disease
• Market Revenue
• Market by Disease Type
• Amyotrophic Lateral Sclerosis
• Progressive Bulbar Palsy
• Hereditary Spastic Paraplegia
• Hereditary Neuropathies (HNs)
• Multiple Sclerosis (MS)

Chapter 7 Market Breakdown by Region

• Introduction
• North America
• The U.S.
• Canada
• Europe
• The UK
• Germany
• France
• Spain
• Italy
• Russia
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• Rest of Asia-Pacific
• Rest of the World
• Market Size and Forecast

Chapter 8 Market Breakdown by Distribution Channel

• Introduction
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Chapter 9 Emerging Technologies and Developments

• Introduction
• Emerging Technology
• Stem Cell Therapy
• Gene Therapy
• Biomarkers
• Nasal Spray for MS
• Disease-modifying Therapies
• RNA-based Therapies
• Conclusion

Chapter 10 ESG Development

• Introduction
• ESG Investments by Key Players
• Consumer Attitudes Towards ESG
• Conclusion

Chapter 11 Patent Analysis

• Patent Analysis by Year

Chapter 12 M&A and Venture Funding Outlook and Competitive Landscape

• Introduction
• Mergers, Acquisitions and Collaborations
• Strategic Initiatives
• Market Shares of Manufacturers of Progressive Ataxia and Weakness Disorders Drugs

Chapter 13 Company Profiles

• ABBOTT LABORATORIES
• ACORDA THERAPEUTICS INC.
• AMERICAN REGENT INC.
• APOTEX INC.
• APOTHECA INC.
• ASTELLAS PHARMA INC.
• ASTRAZENECA GMBH
• BAXTER INTERNATIONAL INC.
• BRISTOL-MYERS SQUIBB
• EISAI CO. LTD.
• ELI LILLY AND COMPANY
• GILEAD SCIENCES INC.
• GLAXOSMITHKLINE PLC
• GLENMARK LIFE SCIENCES
• JOHNSON & JOHNSON
• MERCK KGAA
• NOVARTIS AG
• PFIZER INC.
• ROCHE HOLDING LTD.
• SANOFI
• TAKEDA PHARMACEUTICAL CO. LTD.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.

Chapter 14 Appendix: Abbreviations